A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir (CES1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Agreement with written informed consent
Adult healthy male or female subject age 20 to 45
Clinically significant, active gastrointestinal system, cardiovascular system, pulmonary system, renal system, endocrine system, blood system, digestive system, central nervous system, mental disease or malignancy
Medication with any drug which may affect the pharmacokinetics of oseltamivir within 14 days
Previously donate whole blood within 30 days or Previously participated in other trial within 60 days
Subject with known for hypersensitivity reactions to oseltamivir
Subject who perform contraception during study periods
Female woman who are pregnant or are breast feeding
An impossible one who participates in clinical trial by investigator's decision including laboratory test result